DAGLB (Diacylglycerol Lipase Beta) encodes the enzyme diacylglycerol lipase beta (DAGL-β), which plays a critical role in the biosynthesis of the endocannabinoid 2-arachidonoylglycerol (2-AG)[1]. DAGL-β is one of two diacylglycerol lipase enzymes (along with DAGLA) responsible for converting diacylglycerol (DAG) into 2-AG, the most abundant endogenous cannabinoid in the brain[2]. This enzymatic pathway is essential for endocannabinoid-mediated retrograde signaling at synapses throughout the central nervous system.
The DAGLB gene is highly expressed in brain regions involved in learning, memory, and motor control, including the hippocampus, cortex, basal ganglia, and cerebellum[3]. Recent genetic studies have implicated DAGLB variants in neurodegenerative diseases, including Parkinson's disease and cerebellar ataxias[4][5].
| Attribute | Value |
|---|---|
| Gene Symbol | DAGLB |
| Full Name | Diacylglycerol Lipase Beta |
| Chromosomal Location | 7q31.1 |
| NCBI Gene ID | 27143 |
| Ensembl ID | ENSG00000153048 |
| UniProt ID | Q8WWS3 |
| Protein Length | 672 amino acids |
| Protein Class | Serine hydrolase, lipid hydrolase |
DAGL-β is a membrane-bound enzyme that catalyzes the hydrolysis of diacylglycerol to produce 2-AG[1:1]. The enzyme belongs to the serine hydrolase family and contains the characteristic catalytic triad (Ser-Asp-His) found in lipases. DAGL-β localizes primarily to postsynaptic neurons, where it synthesizes 2-AG in response to neuronal activity.
Key biochemical properties:
The 2-AG biosynthetic pathway involves multiple enzymatic steps:
The produced 2-AG then acts as a retrograde messenger, traveling backward across the synapse to activate presynaptic CB1 receptors, modulating neurotransmitter release[6].
DAGL-β is essential for activity-dependent retrograde signaling in the brain[7]. When postsynaptic neurons are depolarized, intracellular calcium levels rise, triggering DAGL-β to produce 2-AG. This 2-AG then diffuses backward to activate presynaptic CB1 receptors, which inhibit the release of excitatory (glutamate) or inhibitory (GABA) neurotransmitters.
This mechanism allows postsynaptic neurons to dynamically regulate their own input:
Once released, 2-AG activates both CB1 receptors and CB2 receptors[8]:
CB1 receptors: Predominantly expressed in the central nervous system, particularly in presynaptic terminals. Activation inhibits voltage-gated calcium channels, reduces neurotransmitter release, and modulates ion channel activity.
CB2 receptors: Primarily expressed in immune cells including microglia. Activation modulates neuroinflammation and microglial activation states.
Endocannabinoid signaling is profoundly altered in Alzheimer's disease (AD)[9]. DAGL-β dysfunction may contribute to:
Studies show decreased 2-AG levels in AD brains and altered CB1 receptor expression. This dysregulation may represent both a consequence of pathology and a potential therapeutic target.
In Parkinson's disease (PD), DAGLB genetic variants have been associated with disease risk[4:1]. Endocannabinoid signaling is hyperactive in PD, particularly in the basal ganglia, contributing to:
DAGL inhibitors have shown promise in preclinical PD models for reducing dyskinesia while maintaining therapeutic benefit.
The DAGL-β/2-AG pathway plays a complex role in neuroinflammation[10]:
Dysregulated 2-AG signaling may contribute to chronic neuroinflammation characteristic of neurodegenerative diseases.
Endocannabinoid signaling via 2-AG has demonstrated neuroprotective properties[11]:
DAGLB is highly expressed in neurons throughout the brain:
DAGL-β primarily localizes to:
Small molecule DAGL inhibitors are under investigation for treating neurodegenerative diseases[12]:
Potential therapeutic applications:
Alternatively, DAGL activators could enhance 2-AG signaling:
DAGLB mutations cause early-onset progressive cerebellar ataxia in humans[5:1], demonstrating the critical role of this enzyme in motor control and cerebellar function. These findings suggest that modulating DAGL activity must be carefully balanced to avoid disrupting essential physiological functions.
DAGL-β interacts with multiple proteins that regulate its activity and localization:
DAGL-β forms multiprotein signaling complexes at synapses:
DAGL-β employs a serine hydrolase catalytic mechanism:
DAGL-β has multiple isoforms with distinct properties:
DAGL-β knockout and conditional knockout mice have been characterized:
In vitro systems used to study DAGL-β:
DAGL-β dysfunction affects multiple molecular pathways:
DAGL-β dysregulation leads to:
DAGLB encodes diacylglycerol lipase beta, the key enzyme responsible for synthesizing 2-AG, the predominant endocannabinoid in the brain. This enzyme is essential for activity-dependent retrograde synaptic signaling, modulating neurotransmitter release throughout the central nervous system. DAGL-β dysfunction has been implicated in Alzheimer's disease, Parkinson's disease, and cerebellar ataxias, making it a potential therapeutic target. The enzyme's role in neuroinflammation and neuroprotection provides multiple angles for intervention. Further research into DAGL-β modulation may yield treatments for neurodegenerative diseases while avoiding the adverse effects associated with direct cannabinoid receptor agonists.
2-Arachidonoylglycerol: a novel endogenous cannabinoid receptor agonist. Nature. 1997. ↩︎ ↩︎
2-Arachidonoylglycerol in the brain: biosynthesis and signaling functions. J Biochem. 2014. ↩︎
Endocannabinoids: chemistry, biology and pathophysiology. Curr Med Chem. 2006. ↩︎
DAGLB variants in Parkinson's disease. Mov Disord. 2019. ↩︎ ↩︎
DAGLB mutation causes early-onset progressive cerebellar ataxia. Neurology. 2019. ↩︎ ↩︎
CB1 receptor-dependent control of GABAergic plasticity. Nature. 2003. ↩︎
Endocannabinoid signaling at central synapses. J Exp Med. 2009. ↩︎
CB2 receptor in microglial activation and neuroinflammation. J Neurochem. 2009. ↩︎
Endocannabinoid dysfunction in Alzheimer's disease. Nat Rev Neurol. 2022. ↩︎
Anandamide and 2-AG in neuroinflammation. Glia. 2021. ↩︎
CB1 and CB2 cannabinoid receptor agonists in neuroprotection. Br J Pharmacol. 2020. ↩︎
DAGL inhibitors: therapeutic potential in neuroinflammation. J Med Chem. 2020. ↩︎